Physician profile

Mariano Floro

Florissant, MO

NPI 1447330808

$3,360.08

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$455.96

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Organogenesis INC. $1,789.73 2019-2023 Puraply, Affinity
Integra Lifesciences Corporation $574.21 2019-2023 Integra, Tcc-Ez, Primatrix
Smith+Nephew, INC. $526.94 2019-2022
Acera Surgical, INC. $264.62 2021-2022
Hydrofera LLC $78.86 2022
Convatec INC. $29.36 2022
Bioventus LLC $19.60 2022
Apria Healthcare LLC $15.17 2021
Getinge USA Sales, LLC $13.07 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mariano Floro

$3,360.08

in general payments reported 2019-2025

Years
2019-2023
Top company
Organogenesis INC.

https://glasscript.com/doctor/19918/mariano-floro

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.